Indivior Share Discussion Threads

[casholaa] 10/6/2022 15:27

280s on the horizon???

[casholaa] 09/6/2022 18:50

@bint. If she's that good, she doesn't need to have a 'trading website'. She'd be on a super-yacht heading toward one of the islands she just added to her itinerary.

[gregmorg] 09/6/2022 17:37

Also market volumes are pretty thin so its proving easy to manipulate. The Jefferies presentation yesterday seemed very positive with nothing untoward. So we will see what the next few months bring.

[casholaa] 09/6/2022 14:12

23p down today, so far. Low 280s welcome for various reasons.

[timmy11] 09/6/2022 11:59

low 280s would be perfect for me to purchase more

[steeplejack] 09/6/2022 11:22

Could be technical traders hoping to revisit the low 280s.The UK equity market is pretty aimless currently,stocks been manipulated up and down in fairly well trodden trading ranges.

[casholaa] 09/6/2022 11:07

Dunno, the PI is always the last to know anything worth knowing. But, I am pleased that INDV will have the opportunity to take more shares out of circulation at a lower cost. Today we have the ECB interest rates and the US weekly jobless rates. The Markets work in mysterious ways.

[timmy11] 09/6/2022 11:03

at least good for share buy back

[disc0dave45] 09/6/2022 10:56

Some profit taking?, can't see any news to support the drop.

[casholaa] 01/6/2022 15:18

I think it'll be an open road after 337.

[timmy11] 01/6/2022 15:04

Indivior Announces First Patient Included in Aelis Farma's Phase 2b Study Assessing the Efficacy, Safety and Tolerability of AEF0117 in Treatment-Seeking Subjects With Moderate to Severe Cannabis Use Disorder
01/06/2022 2:50pm
PR Newswire (US)

Indivior (LSE:INDV)
Intraday Stock Chart

Wednesday 1 June 2022

Click Here for more Indivior Charts.
SLOUGH, England and RICHMOND, Va., June 1, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) announces the enrollment of the first patient in the Phase 2b study of AEF0117 for the treatment of cannabis use disorder (CUD). This follows less than a year after Indivior and Aelis Farma announced a strategic collaboration that includes an exclusive option and license agreement for the global rights to AEF0117, a first-in-class synthetic Signaling Specific Inhibitor ("SSI") engineered to inhibit the cannabinoid type 1 ("CB1") receptor ("CB1-SSI").

[casholaa] 27/5/2022 15:03

@mwain, there are many opportunities out there. It were not on my radar until I stumbled upon it. I first got in at 140ish and exited at 220ish then back in later at a higher sp, then out then in and all because of them flaming Russians, since then I have stuck with it, the further buyback was totally unexpected on my part and I hope they can take as many shares off the market as possible. I was initially after 320 -oh look! hehe

[mwainw1973] 27/5/2022 14:06

Gutted I passed this up at 40p around the time of the Lupazor issue. Held and bottled it! Well done holders

[casholaa] 27/5/2022 14:05

I see them as a juicy take-over target. The more shares they take off the market benefits us too. I'm hoping for anything over 450 either way, 650 and my body will have a spontaneous reflex reaction. - Their timing is amazing, it's got to be more than luck.

[thorpematt] 27/5/2022 13:36

Very good article in this week's shares magazine, details recent history and future earnings expectations. Summarises that the PER is too cheap given the high margins, future earnings and significant net cash.

[waldron] 27/5/2022 11:06

Indivior to Participate in Jefferies 2022 Healthcare Conference

Slough, UK and Richmond, VA - May 24, 2022 - Indivior PLC (LON: INDV) today announced that Mark Crossley, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will participate in the Jefferies 2022 Healthcare Conference in New York City.



Mark Crossley will present on June 8, 2022, at 8:00 AM (US ET).


The live presentation will be available on Indivior's website www.indivior.com and can also be viewed using the following webcast link: .

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses.


Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD.

Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease.

Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder.

Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide.

Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .

[casholaa] 19/5/2022 10:21

They timed the buyback very well. Truly astonishing.

[casholaa] 13/5/2022 11:11

Let's hope nobody screws things up for us. I feel over-confident now, for better or worse. Good luck all.

[jretlaw] 11/5/2022 12:55

The train is waiting at the station waiting for all to board jump on before it moves off

[casholaa] 09/5/2022 12:21

INDV are very shrewd and/or have some excellent advisors. I do wonder how low they may think the share price may go for the buyback. These people are just stellar in every respect. Respect to them!

[disc0dave45] 05/5/2022 11:05

IMO their share buyback will align with lots of US companies where share buybacks in the S&P500 are at all time highs and clearly US institutional investors like them, all of which should help their proposed US listing.Personally I have mixed views on buybacks, but wouldn't put me off investing. Their 73.5m buyback programme will enhance eps by about 9% when also taking on board their two year conditional share option awards (so about 67m net shares to be cancelled). Such an impact upon eps will obviously reduce the rating and entice more value investors to come aboard - which at present is where the shift seems to be. Biden also wants to raise US tax rates from 21% to 25% so cash flows will be hit and I guess now is the time to maximise buyback programmes.

[waldron] 04/5/2022 19:52

As the purpose of the Program is to reduce the issued share capital of Indivior, to the extent permitted by law, all Ordinary Shares purchased under the Program will be cancelled.